New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper

被引：212

作者：

De Caterina, Raffaele ^{[1
,2
]}

Husted, Steen ^{[3
]}

Wallentin, Lars ^{[4
]}

Andreotti, Felicita ^{[5
]}

Arnesen, Harald ^{[6
]}

Bachmann, Fedor ^{[7
]}

Baigent, Colin ^{[8
]}

Huber, Kurt ^{[9
]}

Jespersen, Jorgen ^{[10
]}

Kristensen, Steen Dalby ^{[3
]}

Lip, Gregory Y. H. ^{[11
]}

Morais, Joao ^{[12
]}

Rasmussen, Lars Hvilsted ^{[13
]}

Siegbahn, Agneta ^{[4
]}

Verheugt, Freek W. A. ^{[14
]}

Weitz, Jeffrey I. ^{[15
]}

机构：

[1] Univ G dAnnunzio, Inst Cardiol, Osped SS Annunziata, I-66013 Chieti, Italy

[2] Fdn Toscana G Monasterio, Pisa, Italy

[3] Univ Aarhus, Aarhus, Denmark

[4] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden

[5] Catholic Univ, Rome, Italy

[6] Univ Oslo, Ulleval Hosp, Oslo, Norway

[7] Univ Lausanne, Lausanne, Switzerland

[8] Univ Oxford, Oxford, England

[9] Wilhelminenhosp, Vienna, Austria

[10] Univ So Denmark, Esbjerg, Denmark

[11] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England

[12] Hosp Santo Andre, Leiria, Portugal

[13] Aalborg Univ, Aalborg, Denmark

[14] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands

[15] McMaster Univ, Hamilton, ON, Canada

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2012年 / 59卷 / 16期

关键词：

acute coronary syndromes; anticoagulants; apixaban; atrial fibrillation; dabigatran etexilate; edoxaban; rivaroxaban; vitamin K antagonists; FACTOR XA INHIBITOR; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; DABIGATRAN ETEXILATE; STROKE PREVENTION; WARFARIN; SAFETY; RIVAROXABAN; PLACEBO;

D O I：

10.1016/j.jacc.2012.02.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral anticoagulants targeting the single coagulation enzymes thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban, and edoxaban) and given in fixed doses without coagulation monitoring. Here we review the pharmacology and the results of clinical trials with these new agents in stroke prevention in atrial fibrillation and secondary prevention after acute coronary syndromes, providing perspectives on their future incorporation into clinical practice. In phase III trials in atrial fibrillation, compared with warfarin, dabigatran etexilate 150 mg B.I.D. reduced the rates of stroke/systemic embolism without any difference in major bleeding; dabigatran etexilate 110 mg B.I.D. had similar efficacy with decreased bleeding; apixaban 5 mg B.I.D. reduced stroke, systemic embolism, and mortality as well as major bleeding; and rivaroxaban 20 mg Q.D. was noninferior to warfarin for stroke and systemic embolism without a difference in major bleeding. All these agents reduced intracranial hemorrhage. Edoxaban is currently being evaluated in a further large phase III trial. Apixaban and rivaroxaban were evaluated in phase III trials for prevention of recurrent ischemia in patients with acute coronary syndromes who were mostly receiving dual antiplatelet therapy, with conflicting results on efficacy but consistent results for increased major bleeding. Overall, the new oral anticoagulants are poised to replace vitamin K antagonists for many patients with atrial fibrillation and may have a role after acute coronary syndromes. Although convenient to administer and manage, they present challenges that need to be addressed. (J Am Coll Cardiol 2012; 59:1413-25) (C) 2012 by the American College of Cardiology Foundation

引用

页码：1413 / 1425

页数：13

共 34 条

[21] Rivaroxaban in Patients with a Recent Acute Coronary Syndrome [J].

Mega, Jessica L. ;

Braunwald, Eugene ;

Wiviott, Stephen D. ;

Bassand, Jean-Pierre ;

Bhatt, Deepak L. ;

Bode, Christoph ;

Burton, Paul ;

Cohen, Marc ;

Cook-Bruns, Nancy ;

Fox, Keith A. A. ;

Goto, Shinya ;

Murphy, Sabina A. ;

Plotnikov, Alexei N. ;

Schneider, David ;

Sun, Xiang ;

Verheugt, Freek W. A. ;

Gibson, C. Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (01) :9-19

[22]

Nagarakanti R, 2008, CIRCULATION, V118, pS922

[23] Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial [J].

Oldgren, Jonas ;

Budaj, Andrzej ;

Granger, Christopher B. ;

Khder, Yasser ;

Roberts, Juliet ;

Siegbahn, Agneta ;

Tijssen, Jan G. P. ;

Van de Werf, Frans ;

Wallentin, Lars .

EUROPEAN HEART JOURNAL, 2011, 32 (22) :2781-2789

[24] Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [J].

Patel, Manesh R. ;

Mahaffey, Kenneth W. ;

Garg, Jyotsna ;

Pan, Guohua ;

Singer, Daniel E. ;

Hacke, Werner ;

Breithardt, Guenter ;

Halperin, Jonathan L. ;

Hankey, Graeme J. ;

Piccini, Jonathan P. ;

Becker, Richard C. ;

Nessel, Christopher C. ;

Paolini, John F. ;

Berkowitz, Scott D. ;

Fox, Keith A. A. ;

Califf, Robert M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :883-891

[25] Antiplatelet agents for the treatment and prevention of atherothrombosis [J].

Patrono, Carlo ;

Andreotti, Felicita ;

Arnesen, Harald ;

Badimon, Lina ;

Baigent, Colin ;

Collet, Jean-Philippe ;

De Caterina, Raffaele ;

Gulba, Dietrich ;

Huber, Kurt ;

Husted, Steen ;

Kristensen, Steen Dalby ;

Morais, Joao ;

Neumann, Franz-Josef ;

Rasmussen, Lars Hvilsted ;

Siegbahn, Agneta ;

Steg, Philippe-Gabriel ;

Storey, Robert F. ;

Van de Werf, Frans ;

Verheugt, Freek .

EUROPEAN HEART JOURNAL, 2011, 32 (23) :2922-2933B

[26] Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) [J].

Ruff, Christian T. ;

Giugliano, Robert P. ;

Antman, Elliott M. ;

Crugnale, Sharon E. ;

Bocanegra, Tomas ;

Mercuri, Michele ;

Hanyok, James ;

Patel, Indravadan ;

Shi, Minggao ;

Salazar, Dan ;

McCabe, Carolyn H. ;

Braunwald, Eugene .

AMERICAN HEART JOURNAL, 2010, 160 (04) :635-U266

[27] A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes [J].

Simoons, ML ;

Bobbink, IWG ;

Boland, J ;

Gardien, M ;

Klootwijk, P ;

Lensing, AWA ;

Ruzyllo, W ;

Umans, VAWM ;

Vahanian, A ;

Van De Werf, F ;

Zeymer, U .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2183-2190

[28] Dabigatran/dabigatran etexilate -: Prevention of DVT prevention of ischemic stroke thrombin inhibitor [J].

Sorbera, LA ;

Bozzo, J ;

Castañer, J .

DRUGS OF THE FUTURE, 2005, 30 (09) :877-885

[29] Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data [J].

Sorensen, Rikke ;

Hansen, Morten L. ;

Abildstrom, Steen Z. ;

Hvelplund, Anders ;

Andersson, Charlotte ;

Jorgensen, Casper ;

Madsen, Jan K. ;

Hansen, Peter R. ;

Kober, Lars ;

Torp-Pedersen, Christian ;

Gislason, Gunnar H. .

LANCET, 2009, 374 (9706) :1967-1974

[30] Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement [J].

Stangier, J ;

Eriksson, BI ;

Dahl, OE ;

Ahnfelt, L ;

Nehmiz, G ;

Stähle, H ;

Rathgen, K ;

Svärd, R .

JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (05) :555-563

← 1 2 3 4 →